The work reports synthesis of twelve novel ethyl 4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives 4(a-f) and 4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-tetrahydropyrimidine-5- CNMR and Mass spectral studies.
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Introduction
Coumarins, an elite class of naturally occurring compounds with promising therapeutic perspectives [1, 2] . This compound have become indispensable structural units that are useful in medicinal chemistry displaying profiles such as anticancer [3] , antioxidant [4] , antiplasmodial [5] , antimalarial [6] , antirhinovirus [7] , antifungal [8] and antibacterial [9] . 4-Oxo-4H-chromen-3-carbaldehyde (3-formylchromone) a useful precursor for the synthesis of several biological active compounds owing to the presence of an unsaturated keto function, a conjugated second carbonyl group at C-3, and an electrophilic centre at C-2. Much research has been focused on the inhibition of bacterial growth by naturally occurring coumarins (xanthoxin, herniarin, umbelliferone, and scopoletin) and on the antifungal activity of umbelliferone, scopoletin, and coumarin itself [10] .
The nitrogen containing heterocycle such as pyrimidine has attracted continuing interest because of its varied biological activities and its occurrence in natural medicinal plants. Pyrimidine and its derivatives are used as pesticides, herbicides and insecticides [11, 12] . Marketed antifungal drugs such as Flucytosine, Voriconazole and Albaconazole, also contain pyrimidine nucleus [13] .
The molecular hybridization (MH) is a strategy of rational design of such ligands or prototypes based on the recognition of pharmacophoric sub-units in the molecular structure of two or more known bioactive derivatives which, through the adequate fusion of these sub-units, lead to the design of new hybrid architectures that maintain pre-selected characteristics of the original templates [14] . It is a new concept in drug design and development to produce a new hybrid compound with improved affinity, potency and efficacy, when compared to the parent drugs [25] . The selection of the two principles in the dual drugs is usually based on their observed (or anticipated) synergistic or additive pharmacological activities to enable the identification of highly active novel chemical entities. Hybrid drugs are basically designed to counterbalance the known side effects associated with the other hybrid part or to amplify its effect through action on another bio target or to interact with multiple targets as one single molecule [16, 17] lowering the risk of drug-drug interactions and minimizing the drug resistance [18] . The designing protocol of the synthesized derivatives is as shown in Table 1 ). These observations make the process under study more expeditious and economic, safe and eco-friendly. The recovery and reusability of the catalyst was investigated for the synthesis of compound 4a. The findings are explained in Table 2 ; the recovered catalyst can be reused at least four additional times in subsequent reactions without a considerable decrease in its catalytic activity. The synthesized derivatives 4(a-f) (1mmol) was allowed to react with hydrazine hydrate (1. Table 4 ). The recovery and reusability of the catalyst was investigated for the synthesis of compound 6a. The findings are explained in Table 5 ; the recovered catalyst can be reused at least four additional times in subsequent reactions without a considerable decrease in its catalytic activity. 
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Chemistry
All chemicals, unless otherwise specified, were purchased from commercial sources and were used without further purification. The major chemicals were purchased from Sigma Aldrich and Avra labs. The development of reactions was monitored by thin layer chromatography (TLC)
analysis on Merck pre-coated silica gel 60 F254 aluminum sheets, visualized by UV light. 
Synthesis of 4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-tetrahydropyrimidine-5-carbohydrazide 6(a-f)
A mixture of ethyl4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivative 4(a-f) ( cold water and then recrystallized from ethanol to afford the pure product.
Scheme 1. Synthesis of the target compounds 4(a-f) and 6(a-f). ethyl 6-methyl-2-oxo-4-(4-oxo-4H-chromen-3-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate [4a]
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